Form 4: Cidara Therapeutics COO & CLO, Shane Ward, Reports Stock Option Grant
SEC Form 4 Filing
Shane Ward, COO & CLO of Cidara Therapeutics, reports the acquisition of stock options.
Summary
- On September 30, 2024, Shane Ward, the COO & CLO of Cidara Therapeutics, Inc., acquired 135,540 employee stock options with an exercise price of $10.75.
- These options vest in 36 equal monthly installments starting from September 30, 2024, and expire on September 29, 2034.
- Following this transaction, Ward directly owns 135,540 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate positive or negative performance, but rather an incentive.
Positives
- The grant of stock options to a key executive like the COO & CLO can be seen as an incentive to align their interests with the long-term success of the company.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting equity if the options are exercised in the future.
- It incentivizes the COO & CLO to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of earliest transaction and vesting commencement date for the stock options. |
| 09/29/2034 | Expiration date of the stock options. |
| 10/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.